Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors

Inclusion criteria:

1. Adult patients with RA according to 1987 American College of Rheumatology (ACR) or 2010 ACR / European League Against Rheumatism (EULAR) classification of RA, with anyRA duration

2. Patient must have ≥ 2 of the following risk factors for ILD (i.e., any 2 or more):

• Male

• Current or previous smoker

• Age of ≥ 60 years at RA diagnosis

• Rheumatoid factor high-positive (titer > 3x upper limit of normal) AND/ORanti-cyclic citrullinated peptide (anti-CCP) high-positive (titer > 3x upperlimit of normal) at RA diagnosis or any time after RA diagnosis

• High/severe RA disease activity score at screening visit or within 12 months ofscreening visit, as defined with any of the following measures: DiseaseActivity Score-28 (DAS-28), Clinical Disease Activity Index (CDAI), RoutineAssessment of Patient Index Data 3 (RAPID-3), Simple Disease Activity Index (SDAI), Patient Activity Scale (PAS), PAS-II

• Presence or history of these extra-articular manifestations of RA: vasculitis,Felty's syndrome, secondary Sjogren's syndrome, cutaneous rheumatoid nodules,serositis and/or scleritis/uveitis

Exclusion criteria:

1. Patients previously diagnosed with any ILD or interstitial lung abnormality (ILA)

2. Patients who have had a chest computerized tomography (CT) in the past 2 years

3. Pregnancy at time of HRCT (to be checked in women of child-bearing potential beforescan)

4. Unwilling or unable to obtain HRCT

5. Patients previously received drugs or treatments that are known to induce ILD (e.g.,radiation therapy to chest region, bleomycin). Note: All disease-modifyingantirheumatic drugs (DMARDs) including methotrexate and biologics are allowed.

6. Patients who have had a lung transplant

7. Patients suspected of having developed ILD due to severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) infection / coronavirus disease 19 (COVID-19) (based onInvestigators' judgement)

8. Patients diagnosed with another autoimmune disorders overlapping with RA-associatedwith the development of ILD (systemic sclerosis, myositis, dermatomyositis, mixedconnective tissue disease, systemic lupus erythematosus, antineutrophiliccytoplasmic antibody (ANCA)-associated vasculitis or primary Sjogren's syndrome)

9. Patients currently enrolled in an investigational new drug trial